Definium Therapeutics, Inc.
Definium Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing psychedelic-based medicines for brain health disorders. The company’s lead program is DT120 ODT, which it is advancing through Phase 3 trials in generalized anxiety disorder (GAD) and major depressive disorder (MDD).
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueDT120 ODT is the company’s lead oral disintegrating tablet program being advanced in late-stage trials.
Additional psychedelic or neuropsychiatric candidates under research and development.
Internal and external trial design, execution, and data generation for regulatory approval.
cGMP production, packaging, and supply of investigational product for trials and launch readiness.
Market access, medical affairs, and launch planning for any approved product.
Customers
The company does not yet sell approved products, so its current “customers” are primarily clinical trial sites, investigators, regulators, and research partners that support development. If approved, its end customers would be physicians, pharmacies, and patients in psychiatry and brain health markets, with distribution constrained by controlled-substance rules.
Research sites, investigators, and CRO-like partners that execute studies and generate data for approval.
FDA and other regulators that determine whether product candidates can advance to market.
Psychiatrists and other physicians who would prescribe DT120 ODT if approved for GAD or MDD.
Adults with anxiety or depression who may use the therapy if it reaches commercialization.
DEA-registered supply chain participants needed to distribute any scheduled product.
Strategy
The company’s strategy is to advance psychedelic-based psychiatry with scientific rigor, centered on completing Phase 3 trials for DT120 ODT in GAD and MDD. It is also preparing for the operational steps needed after approval, including manufacturing, commercialization, and patient access, while preserving liquidity through the development cycle.
Late-stage data is the main value driver and the key step toward approval.
Approval would require manufacturing, distribution, and market access readiness.
The company has no product revenue and depends on external capital to fund R&D.
Geography
Definium is headquartered in New York, with a Canadian corporate base in British Columbia and a U.S. subsidiary in Delaware. Its operating footprint also includes offices in San Diego, Durham, and Madison, reflecting a U.S.-centric development model with cross-border corporate structure. Because it is pre-commercial, geography matters mainly through where trials are run, where management and R&D are located, and where future distribution rules will apply.
Risks
Definium is a pre-revenue clinical-stage company, so its value depends on successful trial outcomes, regulatory approval, and access to capital. Its product candidates are controlled substances, which adds distribution, prescribing, and public-perception risk on top of the usual clinical, manufacturing, and commercialization uncertainties in biotech.
- Clinical development failureImpact: CriticalLikelihood: High
The company’s lead value driver depends on positive Phase 3 results in GAD and MDD.
Exposure: DT120 ODT and other pipeline candidates
- Capital dependenceImpact: HighLikelihood: High
The company has operating losses, no product revenue, and ongoing R&D cash burn.
Exposure - Regulatory and controlled-substance restrictionsImpact: HighLikelihood: Medium
Approval, scheduling, DEA registration, and state monitoring rules can slow uptake.
Exposure: U.S. distribution and prescribing
- Product liability and professional indemnityImpact: HighLikelihood: Medium
Any adverse events in trials or post-approval could trigger claims and reputational damage.
Exposure: Clinical trials and future commercial use
- Public perception of psychedelicsImpact: MediumLikelihood: Medium
Negative publicity may reduce physician willingness to prescribe and patient acceptance.
Exposure: Market adoption in psychiatry
Accounting
Judgemental itemsClinical trial spend, manufacturing, and regulatory work can vary sharply by quarter.
Impact: Affects operating loss comparability and cash burn analysis
Equity awards are common in development-stage biotech and can be significant.
Impact: Inflates non-cash operating expense and reduces comparability
The amended loan agreement and financing warrants may require interest and fair-value treatment.
Impact: Can affect net loss, leverage presentation, and dilution analysis
Clinical and future commercial exposure can require judgmental accruals or disclosures.
Impact: May change reported liabilities and earnings if estimates shift
Similar listed companies
Publicly listed companies with a comparable business focus.
Adial Pharmaceuticals, Inc
ADIL · Pharmaceutical Preparations
Gain Therapeutics, Inc.
GANX · Pharmaceutical Preparations
Ovid Therapeutics Inc.
OVID · Pharmaceutical Preparations
CTT Pharmaceutical Holdings, Inc.
CTTH · Pharmaceutical Preparations
NRX Pharmaceuticals, Inc.
NRXP · Pharmaceutical Preparations
Vanda Pharmaceuticals Inc.
VNDA · Pharmaceutical Preparations
Last updated: 24/09/2026